Evidence map›Paper›PMID 22923501›Full record

ArticleMolecular pharmacology2012

Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

Alae Yaseen, Shuang Chen, Stefanie Hock, Roberto Rosato, Paul Dent, Yun Dai, Steven Grant

Abstract read
In one paragraph

Article in Molecular pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. The Anti-Leukemic Activity of Natural Compounds.Molecules (Basel, Switzerland) · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alae YaseenDepartment of Medicine, Virginia Commonwealth University, P.O. Box 980035, Richmond, VA 23298, USA.
Shuang Chen
Stefanie Hock
Roberto Rosato
Paul Dent
Yun Dai
Steven Grant
Virginia Commonwealth University · US

Funding

SPORE in LymphomaP50CA130805 · NCI · UNIVERSITY OF ROCHESTER · PI FISHER, RICHARD I · 2008 to 2012
$11.7M
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1M
SIGNALING PATHWAYS REGULATING EPITHELIAL CELL SURVIVALR01DK052825 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 1999 to 2013
$3.3M
NF-kappaB Inhibitors and Differentiation-Inducers in LeukemiaR01CA093738 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2002 to 2011
$2.4M
Checkpoint Abrogation and MEK 1/2 Inhibition in MyelomaR01CA100866 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2003 to 2013
$2.2M
OSU-03012 therapy for glioblastomaR01CA141703 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 2010 to 2014
$1.5M
Lapatinib and Obatoclax combination therapyR01CA150214 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 2010 to 2014
$1.5M
NCI NIH HHS 1P50-CA130805-01NCI NIH HHS 1P50-CA142509-01NCI NIH HHS CA100866NCI NIH HHS CA93738NCI NIH HHS P50 CA130805NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA093738NCI NIH HHS R01 CA100866NCI NIH HHS R01 CA141703NCI NIH HHS R01 CA150214NIDDK NIH HHS R01 DK052825
6 · The paper itself

Abstract

Histone deacetylase inhibitors (HDACIs) activate the prosurvival nuclear factor-κB (NF-κB) pathway by hyperacetylating RelA/p65, whereas the chemopreventive agent resveratrol inhibits NF-κB by activating the class III histone deacetylase Sirt1. Interactions between resveratrol and pan-HDACIs (vorinostat and panobinostat) were examined in human acute myelogenous leukemia (AML) cells. Pharmacologically achievable resveratrol concentrations (25-50 μM) synergistically potentiated HDACI lethality in AML cell lines and primary AML blasts. Resveratrol antagonized RelA acetylation and NF-κB activation in HDACI-treated cells. However, short hairpin RNA Sirt1 knockdown failed to modify HDACI sensitivity, which suggests that factors other than or in addition to Sirt1 activation contribute to resveratrol/HDACI interactions. These interactions were associated with death receptor 5 (DR5) up-regulation and caspase-8 activation, whereas cells expressing dominant-negative caspase-8 were substantially protected from resveratrol/HDACI treatment, which suggests a significant functional role for the extrinsic apoptotic pathway in lethality. Exposure to resveratrol with HDACI induced sustained reactive oxygen species (ROS) generation, which was accompanied by increased levels of DNA double-strand breaks, as reflected in γH2A.X and comet assays. The free radical scavenger Mn(III)tetrakis(4-benzoic acid)porphyrin chloride blocked ROS generation, DR5 up-regulation, caspase-8 activation, DNA damage, and apoptosis, which indicates a primary role for oxidative injury in lethality. Analyses of cell-cycle progression and 5-ethynyl-2'-deoxyuridine incorporation through flow cytometry revealed that resveratrol induced S-phase accumulation; this effect was abrogated by HDACI coadministration, which suggests that cells undergoing DNA synthesis may be particularly vulnerable to HDACI lethality. Collectively, these findings indicate that resveratrol interacts synergistically with HDACIs in AML cells through multiple ROS-dependent actions, including death receptor up-regulation, extrinsic apoptotic pathway activation, and DNA damage induction. They also raise the possibility that S-phase cells may be particularly susceptible to these actions.

Indexed as

AcetylationApoptosisCaspase 8Cell Line, TumorDNA DamageDrug SynergismHistone Deacetylase InhibitorsHumansHydroxamic AcidsIndolesLeukemia, Myeloid, AcuteMetalloporphyrinsMitochondriaNF-kappa BPanobinostatReactive Oxygen SpeciesCaspase 8Histone Deacetylase InhibitorsHydroxamic AcidsIndolesmanganese(III)-tetrakis(4-benzoic acid)porphyrinMetalloporphyrinsNF-kappa BPanobinostatReactive Oxygen SpeciesReceptors, TNF-Related Apoptosis-Inducing LigandRELA protein, humanResveratrolSIRT1 protein, humanSirtuin 1StilbenesTranscription Factor RelAVorinostat

Identifiers

PMID22923501
PMCPMC3502626
OpenAlexW2083124809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.